Kaneka Pharma America, LLC
Distributor of life science systems
Based in CA
AI Overview
With $1.2M in lobbying spend across 26 quarterly filings, Kaneka Pharma America, LLC is a significant lobbying presence. Their lobbying covers 1 issue area. Active from 2018 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $250K |
| 2019 | $180K |
| 2020 | $220K |
| 2021 | $190K |
| 2022 | $140K |
| 2024 | $120K |
| 2025 | $110K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Medicare/Medicaid
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment.
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment; H.R. 8999.
Advocacy in support of Medicare Coverage for Dialysis-Related Amyloidosis (DRA) Treatment. H.R. 8999 (118th Cong.).
Advocacy in support of Medicare Coverage for Dialysis-Related Amyloidosis (DRA) Treatment. H.R. 4055 (119th Cong.).
Related Analysis
Related Investigations
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.